Edison, NJ, United States of America

Sridhar Vempati

USPTO Granted Patents = 8 

Average Co-Inventor Count = 6.7

ph-index = 3

Forward Citations = 22(Granted Patents)


Company Filing History:


Years Active: 2021-2025

Loading Chart...
8 patents (USPTO):

Title: Sridhar Vempati: Innovator in Therapeutic Compounds

Introduction

Sridhar Vempati is a notable inventor based in Edison, NJ (US), recognized for his contributions to the field of therapeutic compounds. With a total of 8 patents to his name, he has made significant strides in the development of inhibitors targeting the menin-MLL interaction, which has implications for various diseases.

Latest Patents

Among his latest patents, Vempati has disclosed heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. These compounds are crucial in the development of specific inhibitors of the menin-MLL interaction. Furthermore, he has described pharmaceutical compositions that include these compounds, along with methods for their use in treating autoimmune diseases, heteroimmune diseases, and cancers such as lymphoma and leukemia.

Another significant patent involves substituted pyridines as irreversible inhibitors of the menin-MLL interaction. This patent also details pharmaceutical compositions and methods for using these irreversible inhibitors in combination with other therapeutic agents for treating various diseases dependent on menin-MLL interaction.

Career Highlights

Sridhar Vempati has worked with prominent companies in the pharmaceutical industry, including Biomea Fusion, Inc. and A2a Pharmaceuticals, Inc. His work in these organizations has contributed to the advancement of innovative therapeutic solutions.

Collaborations

Throughout his career, Vempati has collaborated with notable professionals, including Thomas Butler and Jim Palmer. These collaborations have further enhanced his research and development efforts in the field of therapeutic compounds.

Conclusion

Sridhar Vempati's innovative work in developing inhibitors for the menin-MLL interaction showcases his commitment to advancing medical science. His contributions are vital for the treatment of various diseases, and his patents reflect a significant impact on the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…